Press Releases

INCLINE VILLAGE, Nev. , Nov. 5, 2012 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the third quarter and nine months ended September 30, 2012 . (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO ) Royalty revenues for the third quarter of

INCLINE VILLAGE, Nev. , Nov. 5, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced the completion of a structured financing transaction with Wellstat Diagnostics, LLC in which PDL loaned Wellstat $40 million to be used by Wellstat in its development and commercialization

INCLINE VILLAGE, Nev. , Nov. 1, 2012 /PRNewswire/ --   PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its third quarter financial results for the period ended September 30, 2012 , on Monday, November 5, 2012 , after market close.

INCLINE VILLAGE, Nev. , Oct. 9, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) and AxoGen, Inc. (OTCBB: AXGN) announced today that they closed a structured financing transaction on October 5, 2012 , in which PDL provided AxoGen with an aggregate of $20.8 million in exchange for

INCLINE VILLAGE, Nev. , Sept. 14, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the September 14, 2012 , regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of September 7, 2012 , the record date.

INCLINE VILLAGE, Nev. , Sept. 6, 2012 /PRNewswire/ --   PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , the company's president and chief executive officer, will present at the following upcoming conferences. (Logo: 

INCLINE VILLAGE, Nev. , Sept. 6, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced royalty revenue guidance for the third quarter ending September 30, 2012 , of approximately $85 million , as compared with actual royalty revenue of $83 million for the third quarter of

INCLINE VILLAGE, Nev. , Sept. 5, 2012 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for the: (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO ) 2.875% Convertible Senior Notes due February 15, 2015 ( February 2015 Notes) is

INCLINE VILLAGE, Nev. , Aug. 2, 2012 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the second quarter and six months ended June 30, 2012 . (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO ) Royalty revenues for the second quarter of 2012

INCLINE VILLAGE, Nev. , July 19, 2012 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its second quarter financial results for the period ended June 30, 2012 , on Thursday, August 2, 2012 , after the market close.

INCLINE VILLAGE, Nev., June 19, 2012 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that Genentech has notified PDL that Pertuzumab, brand name Perjeta®, is a licensed product. PDL will receive royalties on sales of Perjeta in the quarter following the first quarter of

INCLINE VILLAGE, Nev. , June 14, 2012 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the June 14, 2012 , regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of June 7, 2012 , the record date.

INCLINE VILLAGE, Nev. , June 13, 2012 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced royalty revenue guidance for the second quarter ending June 30, 2012 , of approximately $125 million , as compared with actual royalty revenue of $122 million for the second quarter of

INCLINE VILLAGE, Nev. , June 5, 2012 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for the: (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO ) 2.875% Convertible Senior Notes due February 15, 2015 ( February 2015 Notes) is

INCLINE VILLAGE, Nev. , June 4, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , the company's president and chief executive officer, is scheduled to present at the Jefferies 2012 Global Healthcare Conference on Wednesday, June 6, 2012 , at